Status:
COMPLETED
From Molecules to Cognition: Inhibitory Mechanisms in ASD and NF1
Lead Sponsor:
University of Coimbra
Conditions:
Autism Spectrum Disorder
Neurofibromatosis 1
Eligibility:
All Genders
16-65 years
Phase:
NA
Brief Summary
This study aims to investigate synaptic physiology and behavioral inhibition in patients with NF1 and ASD and to answer whether inhibitory deficits at these levels are modulated by lovastatin. Struct...
Detailed Description
The literature has shown synaptic inhibitory dysfunction in both ASD and NF1. Here the investigators aim to test whether a mechanistic link can be established between that synaptic inhibitory dysfunct...
Eligibility Criteria
Inclusion
- Positive diagnostic results for ASD in:
- The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria.
- Positive diagnostic results for NF1:
- Clinical diagnosis based on the well-established clinical criteria
Exclusion
- Global Intelligence Quotient \< 80
- Associated medical condition such as epilepsy, neurologic conditions, genetic syndromes, or other usual comorbidity in ASD and NF1 populations
- Medication capable of interfering with the intervention and/or study results
- Pregnancy
- Drug use and/or alcohol abuse
- Contra-indications to MR and TMS
Key Trial Info
Start Date :
February 19 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 31 2020
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT03826940
Start Date
February 19 2019
End Date
August 31 2020
Last Update
April 2 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
ICNAS
Coimbra, Portugal, 3000-043